Telazorlimab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameTelazorlimab
Drug Alias NameGBR-830ISB-830
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 inhibitors
TargetsTumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlenmark Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIchnos Sciences SaGlenmark Pharmaceuticals SaAstria Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A